Mymetics’ promising HIV vaccine candidate obtains funding to begin study at Texas Biomedical Research Institute

Epalinges, Switzerland, 29 September 2014

Mymetics Corporation (OTCQB: MYMX), a pioneer in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases across mucosal membranes, announced today that its innovative HIV vaccine candidate will enter a new preclinical trial to confirm excellent results obtained in a previous trial.

Media Name Media Type Description Download
140929 Mymetics - Texas Biomed Release for Gates funding- Final For Distribution PDF Download